Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy

Journal of Translational Medicine

Proceedings

Yi Zhan¹  Fan Zhang¹  Lin-Jun Fan¹  Li Chen¹  Xin-hua Yang¹  Jun Jiang¹  Xiu-wu Bian²  Qing-liang Wang²  Hua-Liang Xiao²  Jin-Long Wu²  Shi-Xin Yang³  Wings TY Loo⁴  Louis WC Chow⁴ 

[1] Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, PRC;Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, PRC;The Third Hospital of Nanchang, Jiangxi, PRC;UNIMED Medical Institute and Organisation for Oncology and Translational Research, Hong Kong, SAR;

关键词: Breast Cancer;    Proliferate Cell Nuclear Antigen;    Pathological Response;    CXCR4 Expression;    Primary Chemotherapy;   

DOI  :  10.1186/1479-5876-10-S1-S3

来源: Springer

【 摘 要 】

BackgroundBiological molecular markers such as proto-oncogene erbB-2 (HER-2/neu, c-erbB-2), the CXC chemokine receptor 4 (CXCR4), estrogen receptor (ER), Proliferating Cell Nuclear Antigen (PCNA), DNA topoisomerase II (topo II), P-glycoprotein (P-gp) and glutathione S-transferase (GST) were observed for changes after administration of neochemotherapy and whether these protein expression changes were correlated with response to chemotherapy.MethodsSixty-four patients with primary breast cancer who had undergone neo-adjuvant chemotherapy were enrolled in the present study. The expressions of C-erbB-2, CXCR4 and ER-α were measured by immunohistochemistry (IHC) on full tissue sections and on tissue microarrays (TMAs). PCNA, TopoII, P-gp and GST were measured by IHC on TMAs. On the other hand, CXCR4, C-erbB-2 and ER-α expressions were detected using western blot analysis to 16 pairs of fresh preoperative core biopsies. The final surgical specimens were obtained from patients with breast carcinoma who received neo-adjuvant chemotherapy and obtained a partial response (PR).ResultsOur data demonstrated that the levels of C-erbB-2, CXCR4 and ER-α in patients decreased after they received neo-adjuvant chemotherapy on full tissue sections and on TMAs. The PCNA level was down-regulated after receiving neo-adjuvant chemotherapy, and no significant change was observed for TopoII, P-gp and GST. The levels of C-erbB-2, CXCR4 and ER-α were also down-regulated after neo-adjuvant chemotherapy was administered, as detected by western blot. In addition, the change expressions of C-erbB-2 and CXCR4 in specimens tended to be correlated with pathological change to neo-adjuvant chemotherapy on full tissue sections and on TMAs in a Pearson chi-square analysis.ConclusionsAs demonstrated in our study, after breast cancer patients were treated with neo-adjuvant systemic therapy, decreased expressions of C-erbB2, ER-α and CXCR4 were observed. Down-regulated expressions of c-erbB-2 and CXCR4 may be a novel mechanism of chemotherapy; the changes of these objective markers may be useful in evaluating the clinical response of neo-adjuvant chemotherapy in breast cancer.

【 授权许可】

Unknown   
© Yang et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.